Search results for: Category

New research from BSWRI offers model to identify progression mechanism of, and therapies for, α-Synucleinopathic neurodegenerative disorders

Baylor Scott & White Research Institute researcher Erxi Wu, Ph.D. recently co-authored a paper published in Nature Communications, demonstrating the successful creation of a mouse model of pure autonomic dysfunction caused by α-Syn pathology. Researchers believe this model could help establish mechanistic links between the transmission of pathological α-Syn and the cardinal features of autonomic dysfunction in α-Synucleinopathy.

Read more

PARTNER 3 Low-Risk Trial: Co-Principal Investigator Examines 2-Year Outcomes With TAVR

Two-year outcomes data on Transcatheter Aortic Valve Replacement (TAVR) in low-risk patients were recently presented at the American College of Cardiology 2020 Annual Scientific Session. PARTNER 3 demonstrated that TAVR with the Sapien 3 valve was as safe and effective as traditional open surgical replacement for low risk patients with aortic stenosis (AS). The primary outcome of the study—the risk of death, stroke or rehospitalization at two years—was comparable between the two groups.

Read more

Newer therapies for overt hepatic encephalopathy, including ammonia scavengers, currently in clinical trials

Approximately one third of patients with cirrhosis who are admitted to the hospital present with altered mental status (AMS). Of those, about 50 percent will have hepatic encephalopathy (HE), a spectrum of reversible neuropsychiatric disorders in patients with chronic liver disease. Other potential causes of AMS include sepsis/infection, metabolic disturbances, drugs/toxins or structural brain lesions.

Read more

Management of non-alcoholic steatohepatitis must focus on obesity treatment

The obesity epidemic in the United States continues to grow. Estimates are that currently 70 percent of the U.S. population is either overweight or obese. In 2013, the American Medical Association recognized obesity as a disease defined as chronic, relapsing, multifactorial and neurobehavioral where an increase in body fat promotes tissue dysfunction and abnormal physical stress to the body because of fat mass.

Read more

Treatment of frailty can improve outcomes for liver transplant recipients

The impact of frailty on outcomes for liver transplant recipients is gaining widespread attention in transplant programs around the world. In numerous studies, frailty has been associated with increased length of stay,   increased hospitalizations, increased costs, and increased mortality. Frailty has even been shown to have as much of an impact on patient survival as a high MELD (Model for End Stage Liver Disease).

Read more